February 18, 2018 |
PET-CT Predicts Lymphoma Survival Better Than Conventional Imaging
September 17, 2014  | 

Sydney, AU - Positron emission tomography/computed tomography (PET-CT) is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular lymphoma, and should be used routinely in clinical practice, according to new research published in The Lancet Haematology. 

“Our findings have important implications for patients with follicular lymphoma, a common and usually slow-growing lymphoma. Compared to conventional CT  scanning, PET-CT is more accurate in mapping-out the lymphoma, and better identifies the majority of patients who have a prolonged remission after treatment,” explains Professor Judith Trotman, study leader and Associate Professor at Concord Hospital, University of Sydney, Australia.

Almost all patients with follicular lymphoma, respond very well to initial treatment with immunochemotherapy, but relapse is common.  Current practice is to use CT imaging to evaluate treatment response. CT, however, cannot easily distinguish patients who are likely to remain in a prolonged remission for several years from those at high risk of early relapse. This creates considerable uncertainty for patients. 

PET-CT is performed using a very small amount of a tracer called 18F-fluorodeoxyglucose (FDG)—glucose containing a radioactive tag—which is injected into the patient. The FDG is highly concentrated in lymphoma cells and so the PET-CT scan will light-up in areas of lymphoma activity. An important goal of therapy is to ‘switch-off’ these lighted areas, obtaining a PET-negative remission. Continue>

Page | 1 2
Suggested Articles